273 related articles for article (PubMed ID: 20297857)
1. Pramipexole extended release: in Parkinson's disease.
Chwieduk CM; Curran MP
CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
7. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Perez Lloret S; Rascol O
Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
[TBL] [Abstract][Full Text] [Related]
9. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
[TBL] [Abstract][Full Text] [Related]
10. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
13. Analysis of pramipexole dose-response relationships in Parkinson's disease.
Wang Y; Sun SG; Zhu SQ; Liu CF; Liu YM; Di Q; Shang HF; Ren Y; Xiang W; Chen SD
Drug Des Devel Ther; 2017; 11():83-89. PubMed ID: 28096656
[TBL] [Abstract][Full Text] [Related]
14. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.
Hauser RA; Schapira AH; Barone P; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W;
Eur J Neurol; 2014 May; 21(5):736-43. PubMed ID: 24834511
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Pinter MM; Pogarell O; Oertel WH
J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.
Mizuno Y; Yamamoto M; Kuno S; Hasegawa K; Hattori N; Kagimura T; Sarashina A; Rascol O; Schapira AH; Barone P; Hauser RA; Poewe W;
Clin Neuropharmacol; 2012; 35(4):174-81. PubMed ID: 22801294
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Olanow CW; Hauser RA; Burdick DJ; Dhall R; de Marcaida JA; Gil RA; Kreitzman DL; Elmer LW; McGarry A; Kieburtz K;
Mov Disord; 2024 Feb; 39(2):350-359. PubMed ID: 37886872
[TBL] [Abstract][Full Text] [Related]
20. Role of pramipexole in the management of Parkinson's disease.
Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
